- /
- Supported exchanges
- / F
- / GOV.F
Insulet Corporation (GOV F) stock market data APIs
Insulet Corporation Financial Data Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Insulet Corporation data using free add-ons & libraries
Get Insulet Corporation Fundamental Data
Insulet Corporation Fundamental data includes:
- Net Revenue: 2 522 M
- EBITDA: 511 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: 0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Insulet Corporation News
New
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference
ACTON, Mass., December 16, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that m...
Assessing Insulet (PODD) Valuation After Recent Share Price Pullback
Insulet (PODD) has been quietly recalibrating after a choppy past month, with the stock down around 11% even as its year to date gain sits in the mid teens, inviting a closer look. See our latest ana...
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
Expansion follows successful multi-year pilots in Massachusetts and California, and longstanding Pod takeback programs in Europe, Canada, and Australia ACTON, Mass., December 15, 2025--(BUSINESS WIRE...
Here is Why Growth Investors Should Buy Insulet (PODD) Now
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.